Skip to main content
. 2018 Dec 7;8:592. doi: 10.3389/fonc.2018.00592

Figure 8.

Figure 8

Representative phase contrast images of the tumor spheres (TS) of (A) OVCAR3 treated with hWJSC-CM; (B) TS of OVCAR3 treated with hWJSC-CL; (C) TS of SKOV3 treated with hWJSC-CM and (D) TS of SKOV3 treated with hWJSC-CL. Decrease in TS size, numbers and cell death/degeneration (indicated by thin black arrows) were more evident following treatment with hWJSC-CL (10, 15, and 30 μg/ml) than with hWJSC-CM (50, 75, and 100%) for 48 h.